Nanoparticle for DSA Removal

Launched by UNIVERSITY OF ZURICH · Feb 17, 2020

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment that uses tiny magnetic particles to help remove specific antibodies from the blood of people with kidney failure. These antibodies, known as donor-specific antibodies (DSA), can make it difficult for patients to receive a kidney transplant from a donor. The researchers will take a sample of blood from participants and use these specially coated nanoparticles to capture and remove the harmful antibodies.

To be eligible for this study, participants must be over 18 years old and have DSA present in their blood, which can be detected using a test called Luminex®. The study is open to all genders, but it’s important that those interested can understand and follow the study procedures. Unfortunately, individuals who are pregnant, breastfeeding, or unable to participate for reasons related to language or mental health will not be eligible. If you join the study, you will be helping researchers learn more about this potential treatment, which could improve the chances of successful kidney transplants for people in need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • DSA in the blood as detected by Luminex®
• • Adults (\>18 years old)
• • Informed written consent
• Exclusion Criteria:
• • Inability to follow the procedures of the study, due to language problems, psychological disorders, social conditions or dementia
• • Pregnancy and/or breast feeding
• • Unwillingness to participate in this study